 SEATTLE, March 17, 2021 PRNewswire -- CTI BioPharma Corp. Nasdaq: CTIC today reported its financial results for the fourth quarter and full year ended December 31, 2020. This past quarter, CTI has executed on the critical clinical, regulatory and commercial activities that will allow for the potential U.S. approval and commercial launch of pacritinib in 2021, said Adam R. 